摘要
目的为有效控制难治复发性弥漫大B细胞淋巴瘤疾病,探究利妥昔单抗联合化疗用于该疾病治疗的可行性、有效性。方法选取我院诊断为难治复发性弥漫大B细胞淋巴瘤的80例患者,随机分为单一组和治疗组,每组均为40例。其中单一组仅使用ECHOP方案控制疾病发展,治疗组使用R-DHAP方案联合利妥昔单抗,对两组患者的临床疗效和不良反应情况进行统计比较。结果单一组临床有效率(27.5%)低于治疗组(62.5%),差异有统计学意义(P<0.05);治疗组肝功能损害、骨髓抑制、胃肠道反应、肾功能损害发生率依次为5.0%、22.5%、25.0%、2.5%,单一组依次为15.0%、40.0%、50.0%、17.5%,单一组均高于治疗组,差异有统计学意义(P<0.05)。结论临床对难治复发弥漫大B细胞淋巴瘤患者治疗时,选择R-DHAP方案化疗,能有效控制瘤体发展,且不良反应少、用药安全性高。
Objective To effectively control the relapsed refractory diffuse large B cell lymphoma and explore the feasibility and effectiveness of rituximab injection and chemotherapy. Methods Eighty patients with relapsed refractory diffuse large B cell lymphoma confirmed in our hospital were selected and randomly divided into single group and treatment group, with 40 cases in each group. The single group just took ECHOP therapy to control the disease development, while the treatment group adopted R-DHAP therapy and rituximab injection. The clinical effect and adverse event were counted. Results The clinical effective rate of the single group （27.5%） was lower than that of treatment group （62.5%）, the difference was statistically significant （P〈O.O5）;the incidence rate of liver function impairment, hone marrow suppression, gastrointestinal reaction and renal dysfunction in the treatment group were 5.0%, 22.5%, 25.0% and 2.5%, while the rate in the single group were 15.0%, 40.0%, 50.0% and 17.5%, the difference was statistically significant （P〈 0.05）. Conclusion For patients with relapsed refractory diffuse large B eel1 lymphoma, the R-DHAP therapy can effectively control the tumor development, reduce the adverse event and improve the clinical safety.
出处
《临床医学研究与实践》
2016年第25期54-55,共2页
Clinical Research and Practice
